MASH Therapies Show Fibrosis Signal in ALD, With Vijay Shah, MD

A phase 2 clinical trial presented at The Liver Meeting 2026 suggests that therapies developed for MASH can effectively reduce fibrosis in patients with alcohol-related liver disease (ALD). The study showed that drugs like semaglutide improved liver biomarkers regardless of alcohol consumption levels.
Why it matters
This finding offers a potential breakthrough for treating ALD, a condition that currently lacks approved pharmacological therapies targeting fibrosis.
Drugs developed for metabolic dysfunction-associated steatohepatitis (MASH) may also improve fibrosis in alcohol-related liver disease (ALD), according to Vijay Shah, MD, who presented phase 2 randomized trial results at The Liver Meeting 2026 in Denver, Colorado.
“If you took a liver of somebody who had MASLD or MASH and somebody who had alcohol, they looked the same,” Shah, a consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic in Rochester, Minnesota, told HCP Live. That histologic overlap is part of why investigators tested agents targeting 3 pathways already being studied in MASH and obesity.
How Did MASH Therapies Affect Fibrosis in ALD?
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in